<DOC>
	<DOCNO>NCT01258595</DOCNO>
	<brief_summary>The aim study generate data key parameter associate assessment influenza vaccine individual 50-64 year age Primary Objective : - To describe immunogenicity High-Dose Trivalent Inactivated Influenza Vaccine ( TIV ) compare TIV . - To describe safety profile High-Dose Trivalent Inactivated Influenza Vaccine , assess solicited adverse reaction collect 7 day post-vaccination , unsolicited adverse event ( include Serious Adverse Events Adverse Events Special Interests ) collect Visit 1 Visit 2</brief_summary>
	<brief_title>A Study High-Dose Trivalent Inactivated Influenza Vaccine Adults 50 64 Years Age</brief_title>
	<detailed_description>Participants randomize receive one dose either High-Dose Trivalent Inactivated Influenza Vaccine Trivalent Inactivated Influenza Vaccine . They follow safety one month post-vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 50 64 year ( inclusive ) day vaccination Informed consent form sign date Medically stable Able attend schedule visit comply trial procedure For woman childbearing potential , use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination Known pregnancy , positive urine pregnancy test Currently breastfeed child Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial vaccination Planned participation another clinical trial present trial period Planned receipt vaccine 4 week follow trial vaccination ( prior Visit 2 blood draw ) Receipt seasonal pandemic influenza vaccine past 6 month Receipt blood bloodderived product past 3 month Systemic hypersensitivity egg , chicken protein , vaccine component , history lifethreatening reaction standarddose Trivalent Inactivated Influenza Vaccine vaccine contain substance Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy Neoplastic disease hematologic malignancy Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination Personal history GuillainBarr√© Syndrome Selfreported seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction might interfere ability comply trial procedure Identified employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member ( i.e. , immediate , husband , wife child , adopt natural ) employee Investigator</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Trivalent Inactivated Influenza Vaccine</keyword>
	<keyword>High-Dose Trivalent Inactivated Influenza Vaccine</keyword>
	<keyword>Influenza vaccine</keyword>
</DOC>